

**Notice Regarding Adjustment of 340B Prices for Select Products of Jazz Pharmaceuticals, Inc.** Jazz Pharmaceuticals, Inc. has recalculated its 340B ceiling prices for the periods Q1 2021 – Q2 2022 for the products listed below due to revisions made to its Medicaid pricing data. Jazz Pharmaceuticals, Inc. has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the public website to ensure transparency by providing access to information about Jazz Pharmaceuticals, Inc.'s recalculation affecting certain 340B Covered Entities for the impacted product. Jazz Pharmaceuticals, Inc. has determined the credit amount owed to each affected Covered Entity. Jazz Pharmaceuticals, Inc. will be working through Apexus, the HRSA 340B Prime Vendor, to issue refunds for each affected Covered Entity. Refunds will be issued either to a Covered Entity's validated wholesaler pharmacy account when one can be identified, or a check will be issued to Covered Entities whose wholesaler account cannot be identified.

<b>NDC</b>	<b>Product Description</b>
68727-0350-01	SUNOSI 75MG 30CT BOTTLE
68727-0351-01	SUNOSI 150MG 30CT BOTTLE

If a Covered Entity believes it is due a refund and is not contacted by Apexus by December 31, 2023, it may contact Jazz Pharmaceutical's Inc., at [MRSinquiries@apexus.com](mailto:MRSinquiries@apexus.com).